Amgen details rare disease ambitions following $28B Horizon acquisition

Six months after Amgen closed its nearly $28 billion acquisition of Horizon Therapeutics, the pharma giant is banking on the rare disease pipeline scored in the deal to buoy its long-term growth.

In a conference call Thursday afternoon, Amgen provided an update on its rare disease ambitions — including a pipeline filled with currently approved products, as well as the new projects it has in the works.